Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors by Wenke Li, Menghui Xu, Mo Cheng, Jing Wei, Lin Zhu, Yu Deng, Fukun Guo, Feng Bi, Ming Liu

Subjects: Get full text

Advances in PD-1/PD-L1 pathway inhibitors in the treatment of thyroid cancer: mechanisms and clinical therapeutic perspectives by Xizi Li, Xizi Li, Siyuan Gao, Chuchu Shan, Chuchu Shan, Qiling Zhang, Qiling Zhang, Ying Tan, Ying Tan, Ying Tan, Xu Yu, Xu Yu, Xu Yu, Jiangyi Yu, Jiangyi Yu, Jiangyi Yu

Subjects: Get full text

Risk factors and outcomes of thyroid immune-related adverse events following PD-1/PD-L1 inhibitors treatment in a large tertiary Chinese center by Wenwen Gong, Erhan Zheng, Minchao Liu, Yaliang Han, Zhaohui Lyu, Qinghua Guo

Subjects: Get full text

PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for Chinese patients with advanced non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomize... by Jianfei Zhang, Min Liu, Dongyang Li, Jiali Luo, Min Wang

Subjects: “…PD-1/PD-L1 inhibitors…”
Get full text